Adagene (ADAG) Competitors

$3.66 -0.04 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.65 -0.01 (-0.27%)

As of 06:48 PM Eastern

ADAG vs. TLRY, STRO, ACRS, PRME, and OCGN

Should you buy Adagene stock or one of its competitors? MarketBeat compares Adagene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adagene include Tilray Brands (TLRY), Sutro Biopharma (STRO), Aclaris Therapeutics (ACRS), Prime Medicine (PRME), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry.

How does Adagene compare to Tilray Brands?

Adagene (NASDAQ:ADAG) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Adagene has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market.

In the previous week, Tilray Brands had 10 more articles in the media than Adagene. MarketBeat recorded 14 mentions for Tilray Brands and 4 mentions for Adagene. Tilray Brands' average media sentiment score of 0.81 beat Adagene's score of 0.80 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Adagene's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Tilray Brands	-156.51%	-3.31%	-2.42%

Adagene currently has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Tilray Brands has a consensus price target of $11.50, suggesting a potential upside of 109.09%. Given Adagene's stronger consensus rating and higher possible upside, equities analysts clearly believe Adagene is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

9.5% of Adagene shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 0.8% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Adagene has higher earnings, but lower revenue than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.61	-$17.61M	N/A	N/A
Tilray Brands	$821.31M	0.78	-$2.19B	-$13.65	N/A

Summary

Adagene beats Tilray Brands on 10 of the 15 factors compared between the two stocks.

How does Adagene compare to Sutro Biopharma?

Adagene (NASDAQ:ADAG) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Adagene has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

In the previous week, Adagene had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for Adagene and 3 mentions for Sutro Biopharma. Adagene's average media sentiment score of 0.80 beat Sutro Biopharma's score of 0.58 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a net margin of 0.00% compared to Sutro Biopharma's net margin of -186.45%.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Sutro Biopharma	-186.45%	N/A	-79.02%

Adagene currently has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Sutro Biopharma has a consensus price target of $40.78, suggesting a potential upside of 6.14%. Given Adagene's stronger consensus rating and higher possible upside, equities analysts clearly believe Adagene is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sutro Biopharma	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

9.5% of Adagene shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Adagene has higher earnings, but lower revenue than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.61	-$17.61M	N/A	N/A
Sutro Biopharma	$102.48M	6.21	-$191.09M	-$26.10	N/A

Summary

Adagene beats Sutro Biopharma on 9 of the 14 factors compared between the two stocks.

How does Adagene compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 4 mentions for Adagene. Adagene's average media sentiment score of 0.80 beat Aclaris Therapeutics' score of 0.12 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Adagene's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Adagene	N/A	N/A	N/A

Aclaris Therapeutics presently has a consensus price target of $11.29, suggesting a potential upside of 135.12%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Given Aclaris Therapeutics' higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene has lower revenue, but higher earnings than Aclaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	85.62	-$64.92M	-$0.56	N/A
Adagene	$7.67M	22.61	-$17.61M	N/A	N/A

Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Adagene has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aclaris Therapeutics beats Adagene on 7 of the 13 factors compared between the two stocks.

How does Adagene compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Adagene (NASDAQ:ADAG) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Prime Medicine had 6 more articles in the media than Adagene. MarketBeat recorded 10 mentions for Prime Medicine and 4 mentions for Adagene. Adagene's average media sentiment score of 0.80 beat Prime Medicine's score of 0.35 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Adagene's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Adagene	N/A	N/A	N/A

Prime Medicine has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Adagene has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Adagene has higher revenue and earnings than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	122.10	-$201.14M	-$1.23	N/A
Adagene	$7.67M	22.61	-$17.61M	N/A	N/A

Prime Medicine presently has a consensus price target of $7.38, suggesting a potential upside of 135.62%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Given Prime Medicine's higher probable upside, equities analysts plainly believe Prime Medicine is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Adagene beats Prime Medicine on 8 of the 15 factors compared between the two stocks.

How does Adagene compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ocugen had 28 more articles in the media than Adagene. MarketBeat recorded 32 mentions for Ocugen and 4 mentions for Adagene. Adagene's average media sentiment score of 0.80 beat Ocugen's score of 0.58 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adagene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Adagene's return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Adagene	N/A	N/A	N/A

Ocugen has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Adagene has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Adagene has higher revenue and earnings than Ocugen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	112.07	-$67.85M	-$0.24	N/A
Adagene	$7.67M	22.61	-$17.61M	N/A	N/A

Ocugen presently has a consensus price target of $9.75, suggesting a potential upside of 567.81%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Given Ocugen's higher probable upside, equities analysts plainly believe Ocugen is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Adagene beats Ocugen on 9 of the 15 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$175.33M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	N/A	18.47	20.90	25.62
Price / Sales	22.61	295.31	549.01	77.56
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	4.88	6.93	9.93	6.96
Net Income	-$17.61M	$24.11M	$3.55B	$333.52M
7 Day Performance	2.23%	0.08%	-0.33%	0.45%
1 Month Performance	-3.94%	0.84%	1.34%	4.06%
1 Year Performance	110.90%	78.10%	41.10%	36.24%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	3.0966 of 5 stars	$3.66 -1.1%	$8.00 +118.6%	+115.1%	$175.33M	$7.67M	N/A	260	Gap Down
TLRY Tilray Brands	3.5481 of 5 stars	$5.69 -3.6%	$11.50 +102.1%	+21.2%	$687.64M	$821.31M	N/A	2,842
STRO Sutro Biopharma	1.9416 of 5 stars	$37.32 -2.8%	$40.78 +9.3%	+385.8%	$636.04M	$102.48M	N/A	240	Earnings Report
ACRS Aclaris Therapeutics	2.9477 of 5 stars	$4.75 +4.9%	$11.00 +131.6%	+317.2%	$632.68M	$7.83M	N/A	100	Earnings Report Analyst Revision
PRME Prime Medicine	2.2733 of 5 stars	$3.39 -2.3%	$7.38 +117.6%	N/A	$626.74M	$4.63M	N/A	N/A	Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. TLRY, STRO, ACRS, PRME, and OCGN

How does Adagene compare to Tilray Brands?

Summary

How does Adagene compare to Sutro Biopharma?

Summary

How does Adagene compare to Aclaris Therapeutics?

Summary

How does Adagene compare to Prime Medicine?

Summary

How does Adagene compare to Ocugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. TLRY, STRO, ACRS, PRME, and OCGN

How does Adagene compare to Tilray Brands?

Which has more risk and volatility, ADAG or TLRY?

Does the media prefer ADAG or TLRY?

Is ADAG or TLRY more profitable?

Do analysts rate ADAG or TLRY?

Do institutionals and insiders have more ownership in ADAG or TLRY?

Which has preferable valuation and earnings, ADAG or TLRY?

Summary

How does Adagene compare to Sutro Biopharma?

Which has more risk and volatility, ADAG or STRO?

Does the media prefer ADAG or STRO?

Is ADAG or STRO more profitable?

Do analysts rate ADAG or STRO?

Do institutionals and insiders have more ownership in ADAG or STRO?

Which has preferable valuation and earnings, ADAG or STRO?

Summary

How does Adagene compare to Aclaris Therapeutics?

Does the media refer more to ACRS or ADAG?

Is ACRS or ADAG more profitable?

Do analysts recommend ACRS or ADAG?

Which has higher earnings & valuation, ACRS or ADAG?

Which has more risk and volatility, ACRS or ADAG?

Do insiders & institutionals hold more shares of ACRS or ADAG?

Summary

How does Adagene compare to Prime Medicine?

Do institutionals & insiders hold more shares of PRME or ADAG?

Does the media refer more to PRME or ADAG?

Is PRME or ADAG more profitable?

Which has more volatility & risk, PRME or ADAG?

Which has stronger earnings and valuation, PRME or ADAG?

Do analysts prefer PRME or ADAG?

Summary

How does Adagene compare to Ocugen?

Do institutionals & insiders hold more shares of OCGN or ADAG?

Does the media refer more to OCGN or ADAG?

Is OCGN or ADAG more profitable?

Which has more volatility & risk, OCGN or ADAG?

Which has stronger earnings and valuation, OCGN or ADAG?

Do analysts prefer OCGN or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools